Piramal Pharma FY26 results: revenue ₹8,869.08 crore

What Piramal Pharma reported for FY2026

Piramal Pharma Limited announced its audited financial results for the year ended March 31, 2026, alongside a set of governance and leadership updates filed with stock exchanges. The company reported standalone revenue of ₹4,782.01 crore for FY2026. On a consolidated basis, revenue stood at ₹8,869.08 crore.

The disclosures also covered profit and loss at both standalone and consolidated levels, and included details such as impairment recognition during the year. Alongside the financial outcome, the Board of Directors approved re-appointments of key leaders and changes in key managerial personnel. The updates matter for investors because they combine audited performance with continuity signals at the board and compliance level.

Standalone performance: profit edged higher

On a standalone basis, Piramal Pharma reported profit after tax (PAT) of ₹700.01 crore for FY2026. This compared with ₹691.40 crore in the previous year, as per the company’s filing.

Standalone revenue for the year was ₹4,782.01 crore. The disclosure did not provide a segment split in the supplied text, but it establishes the audited base for the listed entity’s standalone profitability. For shareholders tracking dividend potential or statutory profitability, the standalone PAT is a key reference point.

Consolidated performance: net loss and impairment

On a consolidated basis, the company reported a net loss after tax of ₹325.94 crore for FY2026. The filing cited operational and exceptional items as factors, including an impairment charge of ₹175.82 crore recognised during the year.

Consolidated revenue for FY2026 was ₹8,869.08 crore. The gap between standalone and consolidated outcomes underscores how group-level accounting, exceptional items, and non-cash charges such as impairment can shift reported profitability. The company’s disclosure, as provided, flags impairment as one of the notable line items influencing the consolidated result.

Board re-appointments: chairperson and executive directors

As part of leadership continuity, the Board re-appointed Ms. Nandini Piramal as Whole-Time Director, designated as Executive Director and Chairperson. Her term is for three years starting April 1, 2027.

The company also re-appointed Mr. Peter DeYoung as Whole-Time Director, designated as Executive Director, for a three-year term effective October 6, 2026. These decisions indicate the board’s intent to retain existing leadership during the next operating cycle following FY2026.

Independent directors: second terms approved

Piramal Pharma’s Board approved the re-appointment of Independent Directors Mr. Sridhar Gorthi and Mr. Peter Stevenson for a second term of five consecutive years, effective March 30, 2027.

In a separate exchange update referenced in the supplied text, Mr. Subramanian Ramadorai’s tenure as an Independent Director concluded, with cessation effective February 9, 2026. The company indicated he would not seek a second term.

Company secretary and compliance officer: transition effective April 29

The company announced a change in key managerial personnel for the company secretary and compliance function. Mr. Maneesh Sharma will join as Company Secretary and Compliance Officer effective April 29, 2026.

He will take over from Ms. Pratibha Mishra, who served as interim lead. The earlier sequence disclosed in the supplied text includes the resignation of Tanya Sanish as company secretary and compliance officer with effect from February 20, 2026, and the appointment of Ms. Pratibha Mishra as interim company secretary and compliance officer with effect from February 21, 2026.

Registered office address to change from April 30, 2026

Piramal Pharma also updated its registered office address in Mumbai. The change will take effect on April 30, 2026, with the company moving to the Ananta Building, Piramal Corporate Park.

Such administrative updates typically matter for statutory communication and regulatory correspondence and are disclosed through exchange filings as part of compliance requirements.

Board meeting, trading window closure, and results process

Separately, the company informed BSE that a Board meeting was scheduled on April 28, 2026, to consider and approve the audited financial results (standalone and consolidated) for the quarter and financial year ended March 31, 2026. The disclosure referenced compliance with SEBI Listing Regulations, including Regulation 29.

The trading window for dealing in the company’s securities was stated to be closed from April 1, 2026 to April 30, 2026 (inclusive). Such closures are standard around price-sensitive announcements to align internal dealing restrictions with disclosure timelines.

Earnings conference call: April 29, 2026

Piramal Pharma also scheduled an earnings conference call on April 29, 2026, from 9:30 AM to 10:15 AM IST to discuss Q4 and full-year FY2026 results with investors and analysts. The supplied text included dial-in details for multiple geographies.

Dial-in numbers provided in the disclosure

• India primary: +91 22 6280 1461 / +91 22 7115 8320
• India toll free: 1 800 120 1221
• USA toll free: 18667462133
• UK toll free: 08081011573

Management commentary referenced earlier in FY2026

In an earlier results communication included in the supplied text (Q3 and 9M ended December 31, 2025), Chairperson Nandini Piramal said FY26 had been “a muted year” due to inventory destocking and slower early-stage order inflows in H1FY26 in the CDMO business. She also pointed to “early signs of recovery” with a pick-up in RFPs and order inflows since October 2025, linked to improved biopharma funding and increased M&A activity in the US healthcare space.

While that commentary predates the full-year audited disclosure, it provides context on the demand environment and the operational backdrop management highlighted during the year.

Key numbers and dates at a glance

Why the update matters for investors

The FY2026 announcement combines audited revenue and profit figures with governance continuity. Standalone profitability improved marginally year-on-year, while consolidated results reflected a reported net loss alongside an impairment charge of ₹175.82 crore, which can materially influence the reported bottom line.

Separately, the leadership decisions and KMP transition are relevant for compliance execution and board stability. The scheduled board meeting, trading window closure, and earnings call timings also indicate a structured disclosure process, which helps investors follow the results cycle and management communication.

Conclusion

Piramal Pharma’s FY2026 disclosures show standalone revenue of ₹4,782.01 crore and consolidated revenue of ₹8,869.08 crore, with standalone PAT at ₹700.01 crore and a consolidated net loss of ₹325.94 crore. The company also announced board re-appointments, a new company secretary from April 29, 2026, and a registered office shift effective April 30, 2026. The next formal touchpoint for investors, as disclosed, is the earnings conference call scheduled for April 29, 2026.